Improving bladder cancer patient care: A pharmacoeconomic perspective

Expert Review of Anticancer Therapy

Volumn 13, Issue 6, 2013, Pages 661-668

  Gore, John L ^a,b   Gilbert, Scott M ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bladder cancer; chemotherapy; comparative effectiveness research; quality of care; quality of life; radical cystectomy

Indexed keywords

BCG VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; MITOMYCIN; PLATINUM COMPLEX; VINBLASTINE;

ANTIBIOTIC PROPHYLAXIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; CYSTOSCOPY; DEEP VEIN THROMBOSIS; DISEASE SPECIFIC SURVIVAL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PATIENT CARE; PROTOCOL COMPLIANCE; REIMBURSEMENT; REVIEW; TOTAL QUALITY MANAGEMENT; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; UNITED STATES; URINARY DIVERSION;

COSTS AND COST ANALYSIS; CYSTECTOMY; FEMALE; HUMANS; MALE; MEDICARE; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIANS; QUALITY OF HEALTH CARE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84879373880     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.58     Document Type: Review

References (60)

1. Starfield B. Primary Care: Balancing Health Needs, Services, and Technology. Oxford University Press, New York, NY, USA (1998).
2. McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to adults in the United States. N. Engl. J. Med. 348(26), 2635-2645 (2003). (Pubitemid 36741592)
3. Pear R. Obama Panel to Curb Medicare Finds Foes in Both Parties. The New York Times, NY, USA, 19 April (2011).
4. Turner SC, Nguyen ES. Improving the Value of Health Care. Nova Science Publishers, New York, NY, USA (2010).
5. Unroe KT, Greiner MA, Hernandez AF et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch. Intern. Med. 171(3), 196-203 (2011).
6. Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK. Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States. BMJ 328(7440), 607 (2004).
7. United States Congressional Budget Office. The Long-term Outlook for Health Care Spending. Congress of the US Congressional Budget Office, DC, USA (2007).
8. Vigen G, Duncan I, Coughlin S. Measurement of Healthcare Quality and Efficiency Resources for Healthcare Professionals. Society of Actuaries, Schaumburg, IL, USA (2011).
9. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18), 1315-1330 (2003). (Pubitemid 38041357)
10. Edge SB, Byrd DR. AJCC Cancer Staging Manual. American Joint Committee on Cancer, Springer, NY, USA (2009).
11. Montie JE, Clark PE, Eisenberger MA et al.; National Comprehensive Cancer Network. Bladder cancer. J. Natl Compr. Canc. Netw. 7(1), 8-39 (2009).
12. Schoenberg MP, Gonzalgo ML. Management of invasive and metastatic bladder cancer. In: Campbell-Walsh Urology. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (Eds). Saunders, PA, USA, 2468-2478 (2006).
13. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280(20), 1747-1751 (1998). (Pubitemid 28536874)
14. Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA Jr. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J. Urol. 167(5), 2012-2016 (2002). (Pubitemid 34309648)
15. Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality after urologic cancer surgery: impact of non-index case volume. Urology 71(5), 906-910 (2008).
16. Gore JL, Lai J, Gilbert SM; Urologic Diseases in America Project. Readmissions in the postoperative period following urinary diversion. World J. Urol. 29(1), 79-84 (2011).
17. Gore JL, Wright JL, Daratha KB et al. Hospital-level variation in the quality of urologic cancer surgery. Cancer 118(4), 987-996 (2012).
18. Gore JL, Yu HY, Setodji C, Hanley JM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Urinary diversion and morbidity after radical cystectomy for bladder cancer. Cancer 116(2), 331-339 (2010).
19. Hollenbeck BK, Miller DC, Taub D et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J. Urol. 174(4 Pt 1), 1231-1237; discussion 1237 (2005). (Pubitemid 41318688)
20. Konety BR, Allareddy V, Herr H. Complications after radical cystectomy: analysis of population-based data. Urology 68(1), 58-64 (2006). (Pubitemid 44037723)
21. Schrag D, Mitra N, Xu F et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 65(6), 1118-1125 (2005). (Pubitemid 40824902)
22. Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J. Natl Cancer Inst. 101(8), 571-580 (2009).
23. Gore JL, Litwin MS, Lai J et al.; Urologic Diseases in America Project. Use of radical cystectomy for patients with invasive bladder cancer. J. Natl Cancer Inst. 102(11), 802-811 (2010).
24. Gore JL, Saigal CS, Hanley JM, Schonlau M, Litwin MS; Urologic Diseases in America Project. Variations in reconstruction after radical cystectomy. Cancer 107(4), 729-737 (2006). (Pubitemid 44232665)
25. Chamie K, Saigal CS, Lai J et al.; Urologic Diseases in America Project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117(23), 5392-5401 (2011).
26. Lotan Y, Cadeddu JA, Roehrborn CG, Stage KH. The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J. Urol. 172(5 Pt 1), 1958-1962 (2004). (Pubitemid 39363101)
27. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Montie JE, Wei JT. The regionalization of radical cystectomy to specific medical centers. J. Urol. 174(4 Pt 1), 1385-1389; discussion 1389 (2005). (Pubitemid 41318736)
28. Gilbert SM, Dunn RL, Hollenbeck BK et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J. Urol. 183(5), 1764-1769 (2010).
29. Gilbert SM, Wood DP, Dunn RL et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 109(9), 1756-1762 (2007). (Pubitemid 46668537)
30. The Dartmouth Atlas of Health Care. American Hospital Publishing, IL, USA (1999).
31. Madeb R, Golijanin D, Noyes K et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 115(12), 2660-2670 (2009).
32. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171(6 Pt 1), 2186-2190, quiz 2435 (2004). (Pubitemid 38625431)
33. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J. Natl Cancer Inst. 95(8), 588-597 (2003). (Pubitemid 36553505)
34. Chamie K, Saigal CS, Lai J et al.; Urologic Diseases in America Project. Quality of care in patients with bladder cancer: a case report? Cancer 118(5), 1412-1421 (2012).
35. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163(4), 1124-1129 (2000). (Pubitemid 30169376)
36. Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J. Urol. 180(2), 520-524; discussion 524 (2008).
37. Messing EM. Urothelial tumors of the bladder. In: Campbell-Walsh Urology. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (Eds). Saunders, Philadelphia, PA, USA, 2407-2446 (2006).
38. Sánchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol. 169(1), 110-115; discussion 115 (2003). (Pubitemid 35461564)
39. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115(5), 988-996 (2009).
40. Hollenbeck BK, Taub DA, Dunn RL, Wei JT. Quality of care: partial cystectomy for bladder cancer-a case of inappropriate use? J. Urol. 174(3), 1050-1054; discussion 1054 (2005). (Pubitemid 41140677)
41. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J. Urol. 170(1), 35-41 (2003). (Pubitemid 36734405)
42. Hedgepeth RC, Zhang Y, Skolarus TA, Hollenbeck BK. Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology 77(2), 385-390 (2011).
43. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003). (Pubitemid 37025405)
44. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 178(2), 451-454 (2007). (Pubitemid 47030482)
45. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol. 29(3), 252-258 (2011).
46. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
47. Porter ME, Teisberg EO. Redefining Health Care: Creating Value-based Competition on Results. Harvard Business School Press, MA, USA (2006).
48. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J. Urol. 170(4 Pt 1), 1085-1087 (2003). (Pubitemid 37108084)
49. Hussey PS, Sorbero ME, Mehrotra A, Liu H, Damberg CL. Episode-based performance measurement and payment: making it a reality. Health Aff. (Millwood) 28(5), 1406-1417 (2009).
50. de Brantes F, Rosenthal MB, Painter M. Building a bridge from fragmentation to accountability-the Prometheus Payment model. N. Engl. J. Med. 361(11), 1033-1036 (2009).
51. Miller DC, Gust C, Dimick JB, Birkmeyer N, Skinner J, Birkmeyer JD. Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff. (Millwood) 30(11), 2107-2115 (2011).
52. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001). (Pubitemid 32120143)
53. Stimson CJ, Chang SS, Barocas DA et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J. Urol. 184(4), 1296-1300 (2010).
54. Birkmeyer NJ, Share D, Campbell DA Jr, Prager RL, Moscucci M, Birkmeyer JD. Partnering with payers to improve surgical quality: the Michigan plan. Surgery 138(5), 815-820 (2005). (Pubitemid 41608473)
55. Flum DR, Fisher N, Thompson J, Marcus-Smith M, Florence M, Pellegrini CA. Washington State's approach to variability in surgical processes/outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP). Surgery 138(5), 821-828 (2005). (Pubitemid 41608475)
56. Share DA, Campbell DA, Birkmeyer N et al. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff. (Millwood) 30(4), 636-645 (2011).
57. Kwon S, Florence M, Grigas P et al. Creating a learning healthcare system in surgery: Washington State's Surgical Care and Outcomes Assessment Program (SCOAP) at 5 years. Surgery 151(2), 146-152 (2012).
58. Kwon S, Morris A, Billingham R et al.; Surgical Care and Outcomes Assessment Program (SCOAP) Collaborative. Routine leak testing in colorectal surgery in the Surgical Care and Outcomes Assessment Program. Arch. Surg. 147(4), 345-351 (2012).
59. Miller DC, Murtagh DS, Suh RS, Knapp PM, Dunn RL, Montie JE. Establishment of a urological surgery quality collaborative. J. Urol. 184(6), 2485-2490 (2010).
60. Miller DC, Murtagh DS, Suh RS et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J. Urol. 186(3), 844-849 (2011).